Your session is about to expire
← Back to Search
JAB-2485 for Advanced Cancer
Study Summary
This trialtests a new treatment for adults with advanced cancer to see if it is safe and tolerable.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have serious eye problems.My organs are functioning well.You must have at least one detectable and measurable abnormality based on specific criteria.I am fully active or restricted in physically strenuous activity but can do light work.My brain metastases are stable with no growth or bleeding for at least 28 days.Your heart's pumping ability is less than 50% as measured by a special heart imaging test.I have active hepatitis B, hepatitis C, or HIV.You need to have a stored tumor sample available for testing.I have not been on antibiotics for an infection in the last week.My condition hasn't improved with current treatments.I can swallow and keep down pills.I do not have any severe or uncontrolled health issues.Your heart's QT interval is longer than 470 milliseconds.My cancer has a specific gene mutation or expression required for the trial.I have side effects from treatment that are moderate or worse and not improving.My cancer is advanced and has been confirmed by lab tests.
- Group 1: JAB-2485 monotherapy, Phase 1, Dose Escalation
- Group 2: JAB-2485 monotherapy, Phase 2a, Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants are actively receiving treatment in this trial?
"Affirmative. Clinicaltrials.gov's records reflect that this research is actively searching for participants, having been initially posted on December 20th 2022 and updated most recently January 4th 2023. The study requires 102 individuals to be admitted into the two sites in question."
Are there any remaining spots available for this clinical research?
"Affirmative. Data hosted on clinicaltrials.gov suggests that this medical trial, initially shared on December 20th 2022, is currently looking for patients to enrol in the study. 102 individuals must be recruited from two different healthcare centres."
What are the aims of this experiment?
"The main efficacy marker of this clinical trial, to be monitored within the initial 21 days of Cycle 1, is the number of participants with adverse events (AEs). Secondary endpoints include: peak plasma concentration (Cmax) as part of PK analyses and assessing food effect on JAB-2485 monotherapy in conjunction with urine or plasma samples; time to response (TTR), recorded from the first treatment to documented complete or partial responses according to RECIST v1.1 criteria; and objective response rate (ORR), measured by percentage of participants who achieved a complete/partial remission under RECIST v1.1 parameters."
Share this study with friends
Copy Link
Messenger